HCW Biologics Inc. 8-K

What Happened
HCW Biologics Inc. announced in an 8-K that on February 26, 2026 it received notice from Nasdaq’s Listing Qualifications Staff that the Nasdaq Hearings Panel found the company had regained compliance with Nasdaq Capital Market continued listing rules, per the Panel’s October 13, 2025 decision letter. The Panel had given HCW extensions to demonstrate compliance with Listing Rule 5550(b)(1) (the “Equity Rule”) by December 31, 2025 and with all other continued listing rules by February 16, 2026.

Key Details

• Nasdaq notice received: February 26, 2026.
• Panel decision date: October 13, 2025.
• Required compliance deadlines the Panel set: Listing Rule 5550(b)(1) by December 31, 2025; all other listing rules by February 16, 2026.
• Company remains subject to a Mandatory Panel Monitor for one year from the January 7, 2026 partial compliance letter; during that period, a new Equity Rule deficiency would trigger a Delist Determination Letter without a cure period, though the company may request a hearing.

Why It Matters
Regaining compliance means HCW Biologics avoids immediate delisting from Nasdaq, which preserves trading access and investor liquidity for now. However, the one-year Mandatory Panel Monitor raises short-term regulatory risk: if Nasdaq finds the same Equity Rule deficiency again during the monitoring period, the company would not get additional cure time and could face a delisting determination and expedited hearing process. Investors should note the elevated oversight and monitor future filings and Nasdaq communications for any signs of renewed noncompliance.